Yuman Fong

Dr. Yuman Fong


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1997 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YFYuman Fong
Yuman Fong
ACA M Cohen
A M Cohen
JFJ G Fortner
J G Fortner
WEW E Enker
W E Enker
ATA D Turnbull
A D Turnbull
MBM F Brennan
M F Brennan
PURPOSE: More than 50,000 patients in the United States will present each year with liver metastases from colorectal cancers. The current study was performed to determine if liver resection for colorectal metastases is safe and effective and to evaluate predictors of outcome. MATERIALS AND METHODS: Data for 456 consecutive resections performed between July 1985 and December 1991 in a tertiary referral center were analyzed. RESULTS: The perioperative mortality rate was 2.8%, with a mortality rate of 4.6% for resections that involved a lobectomy or more. The median hospital stay was 12 days and only 9% of patients were admitted to the intensive care unit. The 5-year survival rate is 38%, with a median survival duration of 46 months. By univariate analysis, nodal status of the primary lesion, short disease-free interval before detection of liver metastases, carcinoembryonic antigen (CEA) level greater than 200 ng/mL, multiple liver tumors, extrahepatic disease, large tumors, or positive resection margin was predictive of poorer outcome. Sex, age greater than 70 years, site of primary tumor, or perioperative transfusion was not predictive of outcome. By multivariate analysis, positive margin, size greater than 10 cm, disease-free interval less than 12 months, multiple tumors, and extrahepatic disease were independent predictors of poorer outcome. Short disease-free interval or multiple tumors were nevertheless associated with a 5-year survival rate greater than 24%. CONCLUSION: Liver resection for colorectal metastases is safe and effective therapy and currently represents the only potentially curative therapy for metastatic colorectal cancer. The only absolute contraindication to resection is extrahepatic disease. A randomized trial to examine efficacy of surgical resection cannot ethically be performed. Liver resection should be considered standard therapy for all fit patients with colorectal metastases isolated to the liver.

1 October 2000 in Annals of Surgery
Verified
Journal Article
Closed access
YFYuman Fong
Yuman Fong
WJWilliam Jarnagin
William Jarnagin
LBLeslie H. Blumgart
Leslie H. Blumgart
To compare patients with gallbladder cancer presenting for therapy with and without prior operation elsewhere to determine if an initial noncurative procedure alters outcome. Nihilism has traditionally surrounded treatment of gallbladder cancer, particularly since the majority of cases are discovered during exploration for presumed gallstone disease when unsuspected cancers cannot be handled definitively and tumor is often violated. Presentation, operative data, complications, and survival were examined for 410 patients presenting between July 1986 and March 2000. In particular, the 248 patients presenting for therapy after prior operation elsewhere were compared with the remainder who presented without prior operation to determine if an initial noncurative procedure alters outcome. Overall Outcome : 51 patients were inoperable, 92 were subjected to exploration and biopsy only, 135 to noncurative cholecystectomy, 30 to surgical bypass, and 102 to potentially curative resections consisting of portal lymph node dissection and liver parenchymal resections. Operative mortality was 3.9%. T-stage predicted likelihood of distant metastases and resectability. Median survival for resected patients was 26 months and 5-year survival was 38%, and for patients not resected, 5.4 months and 4% (P < .0001). Effect of Prior Operation: 22 patients subjected to potentially curative resection as the first surgical procedure were compared to 80 patients resected after prior exploration elsewhere. Mortality, complication, and long-term survival were the same. By multivariate analysis (Cox regression), resectability and stage were independent predictors (P < .001) of long-term survival, but prior surgical exploration was not. Unresected gallbladder cancer is a rapidly fatal disease. Radical resection can provide long-term survival, even for large tumors with extensive liver invasion. Long-term survival can be achieved for patients presenting after prior noncurative surgical exploration.

1 October 2005 in Annals of Surgery
Verified
Journal Article
Closed access
YFYuman Fong
Yuman Fong
MGMithat Gonen
Mithat Gonen
DRDavid Rubin
David Rubin
MRMark Radzyner
Mark Radzyner
MBMurray F. Brennan
Murray F. Brennan
A number of studies have demonstrated that surgical resection at high-volume centers is associated with improved short-term perioperative outcome. Whether long-term results after resection of visceral malignancies are superior at high-volume centers is largely unknown. All patients who were subjected to pancreatectomy or hepatectomy for cancer in the years 1995 and 1996 were identified in the National Medicare database. Data extracted and examined include demographics, comorbidities, and long-term survival. All survival was confirmed through 2001, providing actual 5-year survival. Long-term survival was examined as related to hospital volume. In the study period, there were 2592 pancreatectomies and 3734 hepatectomies performed at 1101 and 1284 institutions, respectively. High-volume center was defined as >25 cases/y. By this definition, there were 10 high-volume centers for pancreatectomy and 12 centers for hepatectomy performing 11% (n = 291) of the pancreatectomies and 12% (n = 474) of the hepatectomies in this study period. Comparison by log-rank demonstrated superior survival for patients resected at high-volume centers (pancreatectomy: P = 0.001; hepatectomy: P = 0.02). This was confirmed by multivariate analysis. All analyses included an adjustment for within-center correlation. Superior long-term survival is associated with complex visceral resections for cancer at high-volume centers.

1 September 2018 in Current Problems in Surgery
Verified
Journal Article
Closed access
CSCamille L. Stewart
Camille L. Stewart
SWSusanne Warner
Susanne Warner
KIKaori Ito
Kaori Ito
MRMustafa Raoof
Mustafa Raoof
GWGeena X. Wu
Geena X. Wu
YFYuman Fong
Yuman Fong

1 January 2003 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PAPeter J Allen
Peter J Allen
NKNancy Kemeny
Nancy Kemeny
WJWilliam Jarnagin
William Jarnagin
RDRonald DeMatteo
Ronald DeMatteo
LBLeslie Blumgart
Leslie Blumgart
YFYuman Fong
Yuman Fong

2 September 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
APAnthony Park
Anthony Park
YFYuman Fong
Yuman Fong
SKSang-In Kim
Sang-In Kim
JYJason Yang
Jason Yang
JMJohn P. Murad
John P. Murad
SPSaul J. Priceman
Saul J. Priceman
An effective combination immunotherapy using oncolytic viruses delivers de novo CD19 to promote CD19-CAR T cell therapy against solid tumors in mice.